CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 230 target
Drug / intervention
BPI-442096drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05369312
NCT05369312Phase 1Unknown
CompareCT.gov

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Betta Pharmaceuticals Co., Ltd.·interventional·Posted May 11, 2022·Updated Jun 21, 2022

In Brief

A Phase 1 clinical trial evaluating BPI-442096 for Solid Tumor and 3 related conditions. Targeting 230 participants across 5 sites.

Detailed Summary

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
CountriesChina
Collaborators--

Timeline

Phase 1UnknownOverdue
2023202420252026
First PostedMay 11, 2022
Enrollment StartJun 1, 2022
Primary CompletionMay 1, 2024
Study CompletionMay 1, 2025
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 4.1 years ago

Interventions

BPI-442096drug

Subjects will receive BPI-442096 until disease progression